Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib-Reference-Cited by-同舟云学术

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib

Published:2021-05-07 Issue:6 Volume:4 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Sakamoto Hiroaki¹²^ORCID,Yanagitani Noriko¹,Manabe Ryo¹,Tsugitomi Ryosuke¹,Ogusu Shinsuke¹,Tozuka Takehiro¹,Yoshida Hiroshi¹,Amino Yoshiaki¹,Ariyasu Ryo¹,Uchibori Ken¹,Kitazono Satoru¹^ORCID,Tasaka Sadatomo²,Nishio Makoto¹^ORCID

Affiliation:

1. Department of Thoracic Medical Oncology The Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan

2. Department of Respiratory Medicine Hirosaki University Graduate School of Medicine Hirosaki Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1414

Reference38 articles.

1. Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

2. Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey

3. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

4. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

5. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer;Investigational New Drugs;2023-04

2. Alectinib/crizotinib;Reactions Weekly;2022-12-17

3. Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study;Translational Lung Cancer Research;2022-12